Gilead files US marketing application for remdesivir
FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen after they announced a Phase 3 Trial of the investigational antiviral drug Remdesivir in patients with severe coronavirus disease (Covid-19), during the outbreak of the coronavirus disease (Covid-19), in Oceanside, California, US, April 29, 2020. REUTERS/Mike Blake/File Photo
Gilead Sciences Inc said on Monday it has filed a marketing application with the U.S. Food and Drug Administration for its experimental Covid-19 drug remdesivir.
Keep updated, follow The Business Standard's Google news channel
